Ulcerative Colitis

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about the search for what triggers the chronic inflammation of Crohn’s disease and ulcerative colitis.

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Research has shown that patients with inflammatory bowel disease, including ulcerative colitis, treated with TNF-alpha blockers have a lower antibody response and a shorter duration of immunity than those who receive integrin receptor antagonists, such as Entyvio (vedolizumab), or no medication at all.

In an observational cohort study published in the September 2023 issue of The Lancet, Jiangwei Sun, Ph.D., from the Karolinska Institutet in Stockholm, Sweden, and his colleagues compared statin users with non-statin users to determine the risk of colorectal cancer in patients with IBD.

The submissions to both the FDA and the EMA are supported by two phase 3 trials demonstrating Skyrizi achieved the primary endpoint of clinical remission.

About 20% to 30% of patients with ulcerative colitis will experience acute severe ulcerative colitis in their lifetime.

A small, open-label study seeds the idea that IL-2 in low doses might be another avenue for treating ulcerative colitis. Low doses may bolster anti-inflammatory T regulatory cells (Tregs) that are believed to lack sufficient expansion in the disease.

70% of inflammatory bowel disease patients managed by in-system specialty pharmacies were adherent to their therapies, according to research findings.

Results reported in the New England Journal of Medicine show that the Eli Lilly drug was superior to placebo in keeping ulcerative colitis in remission.

The favorable results from the 84-patient study may, in part, depend on some of the definitions used.

Legislation designed to smooth the path to exemptions from step therapy has been incorporated into the Pharmacy Benefit Reform Act, one of several bills targeting pharmacy benefit managers that is making legislative headway in the Senate.

Findings by Swedish team of investigators could help identify biomarkers that would predict the response to treatments.

The diagnostic window is a common concept in oncology. The researchers applied it to ulcerative colitis and other conditions.

The researchers suggest more research, including head-to-head trials, to sort out the relative merits of the treatments for ulcerative colitis.

If Morphic Therapeutic's ulcerative colitis drug is approved by the FDA it would likely compete with Entyvio. Pfizer's etrasimod may also enter the fray.

Antibiotic treatment in childhood may disrupt the microbiome and have long-term consequences.

Patients treated with the gut-selective monoclonal antibody were three times more likely to achieve remission of inflammation of ileal pouch-anal anastomosis, an alternative to a life-long colostomy bag after colectomy.

Eli Lilly’s mirikizumab and Pfizer’s etrasimod are expected to be approved by the FDA this year.

By activating the farnesoid X receptor, psyllium may have anti-inflammatory effects.

Authors of a study published in Gastroenterology say results show that an artificial intelligence-based, computer-aided model accurately differentiates disease remission from inflammation.

Guidelines recommend testing for calprotectin and lactoferrin in stool samples and C-reactive protein in the blood.

Crohn's disease and ulcerative colitis can affect food intake and lead to malabsorption of nutrients and intestinal bacterial overgrowth.

The classes with the strongest association with inflammatory bowel disease were those typically used to treat GI infections, nitroimidazoles and fluoroquinolones.

Research by Maria T. Abreu, M.D., and Jacob McCauley, Ph.D., should help fill a gap in the research of the genetics of inflammatory bowel disease, including ulcerative colitis.

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.

Other adverse outcomes were not linked to histological inflammation, according to results of a Swedish study.

Cobitolimod from InDex, a Swedish company, and obefazimod, from Abivax, a French company, could be first-in-class medications for ulcerative colitis.